Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

被引：3

作者：

Los Arcos, Marta Barrado ^{[1
,2
]}

Lopez-Campos, Fernando ^{[3
]}

Valcarcel, Marta Lopez ^{[4
]}

Rubio, Manuel Galdeano ^{[5
]}

de Manzanos, Ignacio Visus Fernandez ^{[1
,2
]}

Duque-Santana, Victor ^{[3
]}

Aparicio, Marian Gomez ^{[6
]}

Martin, Juan Zafra ^{[7
,8
]}

Kishan, Amar U. ^{[9
,10
]}

Achard, Verane ^{[11
,12
]}

Siva, Shankar ^{[13
,14
]}

Counago, Felipe ^{[15
]}

机构：

[1] Hosp Univ Navarra, Pamplona, Navarra, Spain

[2] Inst Invest Navarra IdiSNA, Pamplona, Navarra, Spain

[3] Hosp Univ Ramon y Cajal, Madrid, Spain

[4] Hosp Univ Puerta Hierro, Madrid, Spain

[5] Hosp Terrassa Consorci Sanitari Terrassa, Terrassa, Cataluna, Spain

[6] Hosp Gen Univ Toledo, Toledo, Spain

[7] Hosp Univ Virgen Victoria, Malaga, Spain

[8] Univ Granada, Granada, Spain

[9] Univ Calif Los Angeles, Los Angeles, CA USA

[10] UCLA, Dept Radiat Oncol, Los Angeles, CA USA

[11] Hop Fribourgeois HFR Freiburger Spital HFR, Fribourg, Switzerland

[12] HUG Hop Univ Geneve, Geneva, Switzerland

[13] Peter Maallum Canc Ctr, Melbourne, Australia

[14] Univ Melbourne, Melbourne, Australia

[15] Genesis Care, La Milagrosa Hosp, San Francisco de Asis Hosp, Natl Chair Res & Clin Trials, Madrid, Spain

来源：

CLINICAL GENITOURINARY CANCER | 2023年 / 21卷 / 03期

关键词：

Metastasis-directed therapy; Metastatic prostate cancer; Radiotherapy; METASTASIS-DIRECTED THERAPY; PHASE-II TRIAL; BODY RADIOTHERAPY; MULTICENTER; RECURRENCE; SURVEILLANCE; PROGRESSION; STOMP;

D O I：

10.1016/j.clgc.2022.10.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antian-drogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in differ-ent tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.

引用

页码：E93 / E103

页数：11

共 50 条

[21] Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
Feng Qi
Yihang Xu
Zicheng Xu
Qing Zou
Holistic Integrative Oncology, 4 (1):
[22] Survival and comorbid diabetes mellitus in metastatic hormone-sensitive prostate cancer.
Baxi, Priya
Eaton, Daniel B.
Puri, Varun
Schoen, Martin W.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 74 - 74
[23] Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
Bukhari, Nedal
Potvin, Kvica R.
Ernst, D. Scott
Sax, Lori
Winquist, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[24] Cardiovascular medications and overall survival in metastatic hormone-sensitive prostate cancer.
Pickett, Carley
Eaton, Daniel B.
Tohmasi, Steven
Karunanandaa, Krishny
Gopukumar, Deepika
Puri, Varun
Schoen, Martin W.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 75 - 75
[25] WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
Bisof, Vesna
ACTA CLINICA CROATICA, 2019, 58 (01) : 36 - 41
[26] Soy isoflavones and lycopene in the treatment of hormone-sensitive and hormone-refractory prostate cancer.
Vaishampayan, UV
Forman, JJ
Hussain, M
Cher, M
Pontes, E
Fontana, J
Alluri, KC
Doerge, D
Sarkar, F
Kucuk, O
JOURNAL OF NUTRITION, 2004, 134 (05): : 1258S - 1258S
[27] Metastatic hormone-sensitive prostate cancer
Gravis, Gwenaelle
Salem, Naji
Walz, Jochen
BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
[28] Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer
Gong, Jun
Janes, Jessica L.
Eve, Claire Trustram
Stock, Shannon
Waller, Justin
De Hoedt, Amanda M.
Kim, Jeri
Ghate, Sameer R.
Shui, Irene M.
Freedland, Stephen J.
CANCER, 2024, 130 (22) : 3815 - 3825
[29] Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Preisser, Felix
Chun, Felix. K. -H.
Banek, Severine
Wenzel, Mike
Graefen, Markus
Steuber, Thomas
Tilki, Derya
Mandel, Philipp
PROSTATE INTERNATIONAL, 2021, 9 (03) : 113 - 118
[30] Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer What Is the Standard of Care?
Deek, Matthew P.
Phillips, Ryan
Tran, Phuoc T.
CANCER JOURNAL, 2020, 26 (01): : 87 - 93

← 1 2 3 4 5 →